Neonc Technologies Holdings, INC. (NTHI) — SEC Filings

Overview

Neonc Technologies Holdings, INC. (NTHI) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 24, 2026: On April 23, 2026, Heshmatpour Amir F, a reporting person for NEONC TECHNOLOGIES HOLDINGS, INC., filed a Form 4. This filing details changes in the beneficial ownership of securities for the company. The filing was accepted on the same date.

Sentiment Summary

Across 42 filings, the sentiment breakdown is: 3 bearish, 36 neutral, 3 mixed. The dominant filing sentiment for Neonc Technologies Holdings, INC. is neutral.

Filing Type Overview

Neonc Technologies Holdings, INC. (NTHI) has filed 3 4, 1 EFFECT, 1 S-3, 1 10-K, 22 8-K, 4 S-1, 3 10-Q, 1 8-K/A, 6 S-1/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (42)

• NEONC TECHNOLOGIES HOLDINGS, INC. Form 4 Filing — 4 · Apr 24, 2026 Risk: low
  On April 23, 2026, Heshmatpour Amir F, a reporting person for NEONC TECHNOLOGIES HOLDINGS, INC., filed a Form 4. This filing details changes in the beneficial o
• EFFECT Filing — EFFECT · Apr 10, 2026
• 4 Filing — 4 · Apr 9, 2026
• NEONC TECHNOLOGIES HOLDINGS, INC. Files Form 4 — 4 · Apr 7, 2026 Risk: low
  On April 6, 2026, NEONC TECHNOLOGIES HOLDINGS, INC. filed a Form 4. The filing details changes in beneficial ownership of securities, with the reporting person
• S-3 Filing — S-3 · Apr 2, 2026
• NTHI Accelerates Brain Cancer Trials, Reports Promising NEO100 Data — 10-K · Mar 31, 2026 Risk: high
  NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) is a clinical-stage biopharmaceutical company focused on developing treatments for intracranial malignancies. The compa
• NEONC Tech Enters Material Agreement, Unregistered Equity Sale — 8-K · Mar 23, 2026
  NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K on March 23, 2026, disclosing a material definitive agreement and unregistered sales of equity securities, effect
• NEONC TECHNOLOGIES FILES 8-K REPORT — 8-K · Dec 17, 2025 Risk: low
  On December 15, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and
• NeOnc Faces Mounting Losses Amidst Clinical Trial Progress — S-1 · Dec 15, 2025 Risk: high
  NeOnc Technologies Holdings, Inc. (NTHI) is a clinical-stage biopharmaceutical company focused on developing treatments for intracranial malignancies, including
• 8-K Filing — 8-K · Dec 5, 2025
• NTHI's Net Loss Soars to $46.6M Amidst High Burn Rate, Going Concern Doubts — 10-Q · Nov 14, 2025 Risk: high
  NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) reported a significant net loss of $46,622,106 for the nine months ended September 30, 2025, a substantial increase fro
• NEONC TECHNOLOGIES FILES 8-K — 8-K · Nov 12, 2025 Risk: low
  On November 12, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and
• NEONC TECHNOLOGIES FILES 8-K — 8-K · Nov 10, 2025 Risk: low
  NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K on November 10, 2025, reporting an event on November 7, 2025. The filing pertains to Regulation FD Disclosure and
• 8-K Filing — 8-K · Nov 6, 2025
• NEONC TECHNOLOGIES FILES 8-K FOR REG FD AND EXHIBITS — 8-K · Oct 30, 2025 Risk: low
  On October 28, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and
• NEONC TECHNOLOGIES FILES 8-K — 8-K · Oct 10, 2025 Risk: low
  On October 6, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and E
• NEONC TECHNOLOGIES HOLDINGS, INC. Files 8-K for Material Agreement — 8-K · Oct 9, 2025 Risk: medium
  On October 4, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. entered into a material definitive agreement. The company, incorporated in Delaware with its principal exe
• NEONC TECHNOLOGIES FILES 8-K: REG FD & EXHIBITS — 8-K · Sep 11, 2025 Risk: low
  On September 10, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements an
• NEONC TECHNOLOGIES REPORTS MATERIAL AGREEMENTS & FINANCIALS — 8-K · Aug 22, 2025 Risk: medium
  On August 18, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. reported several key events. The company entered into a material definitive agreement, completed an acquis
• NEONC TECHNOLOGIES: Financial Statements Not Reliable — 8-K/A · Aug 20, 2025 Risk: high
  NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K/A on August 20, 2025, to amend a previous filing. The amendment relates to the company's determination that its p
• NEONC TECHNOLOGIES HOLDINGS, INC. Files Q2 2025 10-Q — 10-Q · Aug 18, 2025 Risk: low
  NEONC TECHNOLOGIES HOLDINGS, INC. filed its 10-Q for the period ending June 30, 2025. The company, operating in pharmaceutical preparations, reported its financ
• NEONC TECHNOLOGIES FILES 8-K REPORT — 8-K · Aug 13, 2025 Risk: low
  On August 7, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Ex
• NEONC TECHNOLOGIES HOLDINGS, INC. Files 8-K for Material Agreement — 8-K · Aug 1, 2025 Risk: medium
  On July 28, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. entered into a material definitive agreement. The company, incorporated in Delaware with its principal execu
• NEONC TECHNOLOGIES Enters Material Definitive Agreement — 8-K · Jul 30, 2025 Risk: medium
  On July 24, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. entered into a material definitive agreement. The company, incorporated in Delaware with its principal execu
• NEONC TECHNOLOGIES FILES 8-K — 8-K · Jul 25, 2025 Risk: low
  On July 22, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and includes Financial Statement
• NEONC TECHNOLOGIES: Material Agreement & Equity Sales — 8-K · Jul 22, 2025 Risk: medium
  On July 16, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. entered into a material definitive agreement, creating a direct financial obligation. The company also repor
• NEONC TECHNOLOGIES FILES 8-K — 8-K · Jul 10, 2025 Risk: low
  On July 8, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhi
• NEONC TECHNOLOGIES HOLDINGS, INC. Files 8-K — 8-K · Jun 12, 2025 Risk: low
  On June 6, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhi
• NEONC Technologies Files S-1 for Public Offering — S-1 · Jun 6, 2025 Risk: high
  NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed an S-1 registration statement on June 6, 2025, for a proposed public offering of its securities, indicating its i
• NEONC TECHNOLOGIES HOLDINGS, INC. Reports Board and Officer Changes — 8-K · Jun 3, 2025 Risk: medium
  On May 28, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. reported changes in its board and officer composition. The company elected new directors and appointed new of
• NEONC TECHNOLOGIES HOLDINGS, INC. Files Q1 2025 10-Q — 10-Q · May 9, 2025 Risk: low
  NEONC TECHNOLOGIES HOLDINGS, INC. filed its 10-Q for the period ending March 31, 2025. The filing details financial information for the first quarter of 2025, i
• NeOnc Technologies Files S-1 for Public Offering — S-1 · Apr 29, 2025 Risk: medium
  NeOnc Technologies Holdings, Inc. filed an S-1 registration statement on April 28, 2025, to register its securities. The company, incorporated in Delaware, is b
• NEONC TECHNOLOGIES: Management & Agreements Update — 8-K · Apr 11, 2025 Risk: medium
  On April 7, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. reported the entry into a material definitive agreement, the departure of directors or certain officers, the
• NEONC TECHNOLOGIES FILES 8-K: Accountant Change & Exhibits — 8-K · Apr 1, 2025 Risk: low
  On March 31, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns changes in the registrant's certifying accountant and in
• NEONC TECHNOLOGIES FILES 8-K: Bylaws & Financials Updated — 8-K · Mar 27, 2025 Risk: low
  On March 25, 2025, NEONC TECHNOLOGIES HOLDINGS, INC. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws, a
• NeOnc Technologies Files S-1/A Amendment — S-1/A · Feb 26, 2025 Risk: medium
  NeOnc Technologies Holdings, Inc. filed an S-1/A amendment on February 26, 2025, for its initial public offering. The company, incorporated in Delaware, is base
• NeOnc Technologies Files IPO Amendment — S-1/A · Jan 31, 2025 Risk: medium
  NeOnc Technologies Holdings, Inc. filed an S-1/A amendment on January 30, 2025, for its initial public offering. The company, incorporated in Delaware, is in th
• NeOnc Technologies Files S-1 for Public Offering — S-1 · Jan 3, 2025 Risk: medium
  NeOnc Technologies Holdings, Inc. filed an S-1 registration statement with the SEC on January 2, 2025, to register securities for a proposed public offering. Th
• NEONC TECHNOLOGIES HOLDINGS, INC. Files Amendment to S-1 Registration Statement — S-1/A · Mar 1, 2024 Risk: low
  NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed a Amended IPO Registration (S-1/A) with the SEC on March 1, 2024. NEONC TECHNOLOGIES HOLDINGS, INC. filed an S-1/
• NEONC TECHNOLOGIES HOLDINGS, INC. Files Amendment No. 3 to S-1 Registration Statement — S-1/A · Feb 23, 2024 Risk: low
  NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed a Amended IPO Registration (S-1/A) with the SEC on February 23, 2024. NEONC TECHNOLOGIES HOLDINGS, INC. filed an
• NEONC TECHNOLOGIES HOLDINGS, INC. Files Amendment No. 2 to S-1 Registration Statement — S-1/A · Feb 5, 2024 Risk: low
  NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed a Amended IPO Registration (S-1/A) with the SEC on February 5, 2024. NEONC TECHNOLOGIES HOLDINGS, INC. filed an S
• NEONC TECHNOLOGIES HOLDINGS, INC. Files Amendment to S-1 Registration Statement — S-1/A · Jan 16, 2024 Risk: low
  NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) filed a Amended IPO Registration (S-1/A) with the SEC on January 16, 2024. NEONC TECHNOLOGIES HOLDINGS, INC. filed an S

Risk Profile

Risk Assessment: Of NTHI's 36 recent filings, 5 were flagged as high-risk, 11 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Neonc Technologies Holdings, INC.'s most recent 10-K filing (Mar 31, 2026):

• Revenue: $0
• Net Income: Not Disclosed
• EPS: Not Disclosed
• Debt-to-Equity: Not Disclosed
• Cash Position: Not Disclosed
• Operating Margin: Not Disclosed
• Total Assets: Not Disclosed
• Total Debt: Not Disclosed

Key Executives

• Heshmatpour Amir F
• 0001443035
• Dr. Ishwar K. Puri
• Amir Farrokh Heshmatpour
• Thomas J. Poletti, Esq.
• Veronica Lah, Esq.
• Dr. Thomas Chen
• Keithly Garnett
• Dr. Thomas C. Chen
• Mitchell S. Nussbaum, Esq.
• Angela M. Dowd, Esq.

Industry Context

NEONC TECHNOLOGIES HOLDINGS, INC. operates in the highly competitive clinical-stage biopharmaceutical sector, specifically targeting intracranial malignancies. This niche is characterized by significant unmet medical needs due to the challenges posed by the blood-brain barrier, leading to poor prognoses for patients. The industry is driven by innovation in drug discovery, novel delivery systems, and advancements in areas like AI-driven research, as evidenced by NTHI's recent IP acquisition. Companies in this space face long development cycles, high R&D costs, and stringent regulatory hurdles.

Top Tags

disclosure (9) · financials (8) · material-agreement (7) · pharmaceuticals (6) · 8-k (5) · sec-filing (5) · Emerging Growth Company (4) · filing (4) · ipo (4) · S-1/A (4)

Key Numbers

• Aggregate market value of common equity held by non-affiliates: $67.9 million — as of June 30, 2025, indicating market capitalization
• Shares of common stock outstanding: 23,806,216 — as of March 30, 2026
• Total purchase consideration for IP acquisition: $3.5 million — in 2025, including cash and common stock
• Radiographic response rate for NEO100: 21% — in combined analysis of 24 patients, exceeding historical <8%
• Six-month progression-free survival (PFS-6) for NEO100: 44% — compared to historical 21–31% for recurrent IDH1-mutant high-grade glioma
• Overall survival for NEO100 patients: 33% — 8 of 24 patients remained alive for at least 18 months
• Recommended Phase 2 dose (RP2D) for oral NEO212: 610 mg — established after Phase 1 dose escalation
• Projected readout for NEO100 Phase II studies: 2024 — advancing original timeline by a full year from 2025
• Total Revenue: $39,990 — Generated from January 1, 2023, to September 30, 2025, indicating minimal commercial activity.
• Net Loss for 2023: $14,921,065 — Reflects significant operational expenses without corresponding revenue.
• Net Loss for 2024: $11,898,464 — Continued substantial losses, though slightly lower than 2023.
• Net Loss for 9 months ended Sep 30, 2025: $46,622,106 — A sharp increase in losses compared to the prior year, indicating accelerated burn rate.
• Net Loss for 9 months ended Sep 30, 2024: $9,645,482 — Baseline for comparison to the significantly higher 2025 loss.
• Accumulated Deficit as of Sep 30, 2025: $97,230,551 — Highlights the company's substantial historical losses and negative equity.
• Shares Offered by Selling Stockholders: 111,732 — Represents the number of common stock shares being offered, with no proceeds to the company.

Related Companies

NEON

Frequently Asked Questions